1973-LB: Postpartum Dysglycemia Screening with Continuous Glucose Monitoring

Introduction 40% non-Hispanic White, 24% non-Hispanic Black, 22% Asian, 14% Hispanic; 34% Medicaid insured) were consented; 86% returned CGM and 66% completed OGTT. All CGM downloads included at least 72 hours of data, and 19% provided data after recent steroid administration. Fasting data was available on 88% of CGM and 42% of OGTT. Mean CGM glucose was 122±14 mg/dL. Median time 140, 180, and 200 mg/dL was 17%, 1.9%, and 0.6%, respectively; and 91%, 21%, and 33% had time 140 mg/dL of 5%, 180 mg/dL of 5%, and 200 mg/dL of 1%. Mean fasting CGM glucose was 113±15 mg/dL and was 100-125 mg/dL in 51% and 125 mg/dL in 23%. Dysglycemia on OGTT (7 impaired glucose tolerance, 1 diabetes) was well predicted by percent time 180 of 4% (sensitivity 86%, specificity 85%, positive predictive value 60%, negative predictive value 96%). Removal of steroid affected data did not improve performance. CGM and OGTT were considered burdensome by 7% and 52%, respectively. Conclusion: Completion rates and acceptability scores were better for CGM than OGTT. Percent time 180 mg/dL had strong predictive power for OGTT. Time above range for this population was also found to be higher than reported for people without diabetes. Disclosure C. Cabrera: None. S.J. Ogyaadu: None. L. Kaplan: None. A. Ipek: None. C.J. Levy: Research Support; Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; MannKind Corporation, T1D Exchange, Tandem Diabetes Care, Inc., Abbott, Insulet Corporation. G. O'Malley: Research Support; Dexcom, Inc., Insulet Corporation, Abbott, Tandem Diabetes Care, Inc., MannKind Corporation. Funding Product and research support for this investigator initiated study provided by Dexcom, Inc.